Cadence raises $100M to automate chronic care at home

Cadence closes $100M Series C to scale remote chronic care

Cadence, a New York-based startup, raised $100 million in Series C funding led by Spark Capital on Tuesday. The round brings total fundraising to $241 million and values the company at $1.23 billion. Spark Capital, an early backer of Anthropic, was joined by Thrive Capital (an OpenAI investor), General Catalyst, Coatue, B Capital, and the venture arms of three health systems: Corewell Health, Memorial Hermann, and Duke Health.

The company operates a medical group of more than 300 staff members, including physicians, nurses, and nurse practitioners. These clinicians deliver care 24 hours a day, seven days a week under the white-label brand of partnering health systems. Cadence currently cares for more than 100,000 patients across eight health system partners, including Providence, Yale New Haven Health, Hackensack Meridian Health, Lifepoint Health, Community Health Systems, Hartford HealthCare, and Rush University System for Health (company-reported).

The platform monitors patients at home via connected devices, tracks vitals in real time, and adjusts medications automatically. Cadence also uses AI to predict adverse events like strokes and heart attacks before they occur. CEO Chris Altchek founded the company in 2020 on the thesis that treatment of heart failure, hypertension, and diabetes could be moved out of the clinic and into the home.

The underlying problem is not new, but the investor appetite is

Chronic disease management in the U.S. has long been a matter of routine clinic visits, typically occurring a few times per year. The outcomes reflect that model's limitations: fewer than 30% of U.S. adults with high blood pressure ever achieve control, and fewer than 10% of heart failure patients are on the correct medications at any given time (per the article, citing observed data patterns in the U.S. healthcare system).

What has changed is the combination of two things. First, home monitoring devices have become reliable enough to replace episodic clinic assessments. Second, AI can now flag deviations and trigger protocol-driven interventions without requiring a physician to manually review every data point. Altchek's framing is clear: "Taking care of patients in a couple clinic visits every time they come and see their primary care provider a couple times a year doesn't work."

The investor consortium—particularly the health systems themselves taking equity stakes—indicates that large health systems now see this as a credible answer. Health systems investing venture capital rarely bet on monitoring dashboards. They invest in clinical models that they believe can shift clinical outcomes and reduce their own cost of care. Cadence's structure, where health systems white-label the company's medical staff, is critical to that thesis: it avoids the friction of integration and allows the health system to maintain brand control while outsourcing the operational and clinical burden.

For health system leaders: expect competitive pressure on remote chronic care coverage

If your health system does not currently offer 24/7 remote management for high-risk chronic disease patients, competitive peers now have a venture-backed playbook. Cadence's model removes the traditional barriers: you do not need to hire and retain a separate medical group; the company handles that and white-labels under your brand.

The question is not whether to build or buy, but whether the financial case works for your population. Cadence's funding round suggests that multiple large health systems have already done that math and answered yes. The next step is to audit your current chronic disease pathways for gaps in monitoring frequency and medication adherence—those are the exact variables Cadence targets.